Regeneron Pharmaceuticals, Inc. (REGN) News
Track canonical SquawkNews coverage tagged to REGN, Regeneron Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 37 indexed stories across 23 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Regeneron Pharma Price Target Maintained With a $737.00/Share by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 12:45 PM UTC
L
RBC Capital reiterates Sector Perform rating on Regeneron Pharmaceuticals, $737 price target
RBC Capital reiterated their Sector Perform rating on Regeneron Pharmaceuticals's stock with a price target of $737.00.The price target implies a downside of 2.0% from the Sep 28 close of $752.25.Key takeaways from the a
EQUITY | Sep 29, 2026, 12:36 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Weekly Recap: EYLEA, DUPIXENT and LIBTAYO growth and Q3 2026 results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) heads into its Oct. 30 premarket Q3 2026 report after strong growth driven by EYLEA HD, DUPIXENT and LIBTAYO, highlighting upcoming C5, hem—onc and Factor XI data readouts as
EARNINGS | Sep 28, 2026, 11:05 AM UTC
H
Regeneron Pharmaceuticals, Inc. (REGN) Sets Q3 Results Date
Regeneron will report third quarter 2026 financial and operating results on Oct 30, 2026, before U.S. markets open, and host a call at 8:30 AM ET.Material DetailsContext by AI AnalystThis is a routine scheduling notice a
EARNINGS | Sep 24, 2026, 08:11 PM UTC
L
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, b
NEWS | Sep 24, 2026, 08:11 PM UTC
M
Regeneron to report Q3 2026 results Oct. 30
Regeneron said it will report third-quarter 2026 financial and operating results and host a conference call and webcast on Oct. 30, 2026.
EQUITY | Sep 24, 2026, 08:05 PM UTC
L
RBC says AI weakness appears to be fueling biotech rally
RBC SAYS AI WEAKNESS APPEARS TO BE FUELING BIOTECH RALLYWeakness in artificial intelligence-related stocks may be helping fuel a biotech rally as investors shift money from volatile technology shares into healthcare stoc
EQUITY | Sep 23, 2026, 01:15 PM UTC
L
REGN: Strong growth in Dupixent and EYLEA HD, with new launches and pipeline assets driving future momentum
Dupixent continues to drive growth with strong performance across multiple indications and high adherence, while new pipeline assets and strategic collaborations aim to sustain leadership in immunology. Cemdisiran is poi
NEWS | Sep 14, 2026, 06:49 PM UTC
L
HSBC raises Regeneron Pharma price target to $920 from $800
HSBC maintained Regeneron Pharma at Buy and raised its price target to $920.00 per share from $800.00, according to TradingView News ratings actions reported by Benzinga.
EQUITY | Sep 10, 2026, 01:48 PM UTC
L
Sanofi and Regeneron eye extending Dupixent US patent to 2033
Market talk says Sanofi and Regeneron could extend Dupixent’s U.S. patent by two years to 2033, with RBC Capital Markets citing a 70% chance in a research note.
EQUITY | Sep 09, 2026, 02:49 PM UTC
L
RBC starts EU pharma coverage with Outperform ratings for AstraZeneca, Roche
RBC Capital Markets launched EU pharma coverage: Outperform for AstraZeneca and Roche, and Sector Perform for Sanofi, Novartis and GSK.
EQUITY | Sep 09, 2026, 02:43 PM UTC
H
REGN: Record sales, pipeline milestones, and strategic collaborations drive robust growth outlook
Strong financial results were driven by record sales of key products and enhanced profit recognition from collaborations. The pipeline is advancing with pivotal data and regulatory milestones expected, while commercial e
EARNINGS | Sep 09, 2026, 02:27 PM UTC
L
REGN: Record sales, pipeline catalysts, and strategic collaborations drive robust growth and future innovation
Strong financial growth was driven by record sales in key franchises and full profit recognition from collaborations. Pipeline catalysts, including new launches and pivotal data, are expected in 2026, while strategic col
EQUITY | Sep 09, 2026, 01:48 PM UTC
L
REGN - REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Infor
REGN - REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses
EQUITY | Aug 20, 2026, 02:26 AM UTC
L
Regeneron (REGN) announces investor conference presentation schedule
Regeneron (REGN) announces investor conference presentations, with no additional details on timing, content, or disclosures provided in the feed.
EQUITY | Aug 19, 2026, 08:05 PM UTC
M
FDA approves pasatru (garetosmab-grts) for FOP adults
Regeneron Pharmaceuticals (REGN) says the FDA approves pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva.
REGULATION | Aug 19, 2026, 05:59 PM UTC
H
FDA approval for REGN Pasatru™ in adult FOP patients
Regeneron (REGN) says Pasatru™ (garetosmab-grts) is the first and only FDA-approved treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in a placebo-controlled adult FOP trial.
EQUITY | Aug 19, 2026, 05:58 PM UTC
M
U.S.-China biotech rivalry drives pharma dealmaking, policy scrutiny
China has pulled ahead of the United States in two of six domains in a June Cure Innovation Index survey, while U.S. agencies and lawmakers move to screen biotech ties and licensing deals continue.
GEOPOLITICS | Aug 13, 2026, 02:41 AM UTC
H
Regeneron Stock Drops 9%
Regeneron stock falls after clinical trials
EQUITY | Aug 04, 2026, 10:36 AM UTC
L
Regeneron Awards $150,000 Prize
Regeneron awards innovation prize
EQUITY | Jul 31, 2026, 11:00 AM UTC
H
Regeneron Q2 EPS $14.29
Regeneron beats Q2 EPS estimate
EARNINGS | Jul 30, 2026, 11:52 AM UTC
H
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlo
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlook FY CAPEX $1,030-1.100B, Q2 dupixent global net sales rise 38% to $6B, Q2 eyle
EARNINGS | Jul 30, 2026, 10:31 AM UTC
L
REGN - Regeneron Reports Second Quarter 2026 Financial and Operating Results
REGN - Regeneron Reports Second Quarter 2026 Financial and Operating Results
EQUITY | Jul 30, 2026, 10:30 AM UTC
H
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, P
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, PWR +/-11.7%, ALNY +/-9.9%, XEL +/-6.3%, MO +/-3.3%, SO +/-2.0%, YUM +/-6.0%, CI
EARNINGS | Jul 29, 2026, 06:05 PM UTC
H
REGN Earnings pre-market tomorrow: qtr EPS est $10.26 (high $12.33/low $7.64), 30-day avg EPS revision -8.4% (0 analyst(s) revised up, 14 do
REGN Earnings pre-market tomorrow: qtr EPS est $10.26 (high $12.33/low $7.64), 30-day avg EPS revision -8.4% (0 analyst(s) revised up, 14 down), qtr revs est $3.82B; FY EPS est $45.74, FY revs est $15.91B; short interest
EARNINGS | Jul 29, 2026, 05:07 PM UTC
L
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGULATION | Jul 24, 2026, 06:52 PM UTC
L
BDX REGN SJM session highs
BDX REGN SJM session highs
EQUITY | Jul 14, 2026, 05:13 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
Regeneron price target lowered to $769 from $778 at Truist
Truist lowered the firm's price target on Regeneron to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a t
EQUITY | Jul 07, 2026, 01:13 PM UTC
H
Regeneron price target lowered to $696 from $707 at RBC Capital
RBC Capital lowered the firm's price target on Regeneron to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has pick
RATES | Jul 07, 2026, 11:27 AM UTC
L
Regeneron price target lowered to $800 from $990 at HSBC
HSBC lowered the firm's price target on Regeneron to $800 from $990 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperforman
EQUITY | Jul 06, 2026, 02:25 PM UTC
H
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilienc
MACRO | Jun 30, 2026, 02:17 PM UTC
M
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
REGULATION | Jun 29, 2026, 06:55 PM UTC
H
WHO: Ebola Outbreak Outpacing Response
The Ebola outbreak is continuing to outpace the response, according to WHO director Tedros.
EQUITY | Jun 24, 2026, 01:31 PM UTC
H
REGN: FDA, EMA Accept Cemdisiran Apps
Regeneron Pharmaceuticals announces FDA and EMA acceptance of regulatory applications for cemdisiran to treat generalized myasthenia gravis
EQUITY | Jun 22, 2026, 11:10 AM UTC
L
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGULATION | Jun 22, 2026, 11:00 AM UTC